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Abstract
Background: A high-sensitivity cardiac troponin T (hs-cTnT) concentration above the 99
th percentile (i.e. 14 ng/L) is
common during Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and associated with
increased mortality. The objective of the study was to identify factors associated with hs-cTnT levels during
AECOPD.
Methods: We included 99 patients with AECOPD on admission. As 41 patients had one or more repeat admissions,
there were 202 observations in the final analysis. We recorded clinical and biochemical data, medication, spirometry,
chest radiographs, and ECGs. The data were analysed for cross-sectional and longitudinal associations using ordinary
least square as well as linear mixed models with the natural logarithm of hs-cTnT as the dependent variable.
Results: Mean age at inclusion was 71.5 years, mean FEV1/FVC was 45%, and median hs-cTnT was 27.0 ng/L. In a
multivariable model there was a 24% increase in hs-cTnT per 10 years increase in age (p<0.0001), a 6% increase
per 10 μmol/L increase in creatinine (p=0.037), and a 2% increase per month after enrollment (p=0.046). Similarly,
the ratios of hs-cTnT between patients with and without tachycardia (heart rate ≥100/min) and with and without
history of arterial hypertension were 1.25 (p=0.042) and 1.44 (p=0.034), respectively. We found no significant
association between arterial hypoxemia and elevated hs-cTnT.
Conclusion: Age, arterial hypertension, tachycardia, and serum creatinine are independently associated with the
level of hs-cTnT on admission for AECOPD.
Background
Cardiovascular disease (CVD) is frequent in chronic ob-
structive pulmonary disease (COPD) [1-5]. This is in part
due to cigarette smoking being a strong common risk fac-
tor, but systemic effects of COPD are thought to independ-
ently promote CVD [6]. The role of systemic inflammation
in the development of CVD is well established [7,8], and it
is proposed that “systemic spill-over” from lung inflamma-
tion in COPD may explain the increased cardiovascular risk
among these patients, both in general and particularly post
exacerbation [6,9-12]. However, not only atherosclerotic
heart disease, but also heart failure and arrhythmias are
more common among COPD patients than in the general
population [1-5].
We recently showed that myocardial injury, defined as
high-sensitivity cardiac troponin T (hs-cTnT) above the
99
th percentile (i.e. 14 ng/L), was present in 74% of patients
admitted for acute exacerbation of COPD (AECOPD) and
that such injury carried a markedly increased risk of subse-
quent mortality [13]. We proposed four possible mechan-
isms, that may occur in concert, leading to elevated hs-
cTnT during AECOPD: Type 1 and 2 myocardial infarc-
tions (MI), increased right heart afterload due to either
AECOPD alone or pulmonary embolism, and concomitant
left heart failure. The determinants of troponin elevation in
AECOPD are, however, sparsely studied.
In a previous cross-sectional study among patients
hospitalised for AECOPD, we found that cardiac
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th generation assay was
positively associated with increasing serum creatinine,
blood neutrophil cell count, and cardiac infarction injury
score (CIIS), whereas it was negatively associated with
hemoglobin level [14]. In that retrospective study, tropo-
nins were measured at the discretion of the attending
physician in selected patients, which may have intro-
duced a selection bias. In the present study we prospect-
ively obtained data from patients hospitalised for
AECOPD one or more times during the study period,
thereby providing the opportunity to study the associ-
ation between hs-cTnT and relevant covariables within
patients, and reducing the influence of inter-individual
differences.
Our objective was to identify clinical factors that are
associated with the level of hs-cTnT in patients admitted
with AECOPD using cross-sectional as well as longitu-
dinal analyses of the association between these determi-
nants and concurrent hs-cTnT.
Methods
During 23 months in 2005 and 2006 we prospectively
included 99 unselected patients admitted with AECOPD.
Among these, 41 patients had data recorded on readmis-
sion during the inclusion period, and in total we gath-
ered data on 219 admissions. On each admission we
recorded heart rate (HR), blood pressure (BP), body
temperature, respiratory rate, arterial blood gas (pH,
PaCO2, PaO2), arterial oxygen saturation (SaO2), use of
accessory respiratory muscles, wheezing, and chest pain.
Mean arterial pressure (MAP) was estimated by the for-
mula MAP=1/3*systolic BP+2/3*diastolic BP.
Serum and plasma from blood drawn on admission
were stored at −80 °C for subsequent analysis of creatin-
ine and hs-cTnT (cobas e 411 immunoanalyser, Roche
diagnostics). According to the manufacturer of the hs-
cTnT assay, the lower limit of detection is 3.0 ng/L, and
the 99
th percentile in healthy volunteers was 14 ng/L.
The lowest hs-cTnT level with 10% coefficient of vari-
ation was 13 ng/L. Glomerular filtration rate (GFR) was
estimated by MDRD and Cockcroft-Gault formulae
[15,16]. From the hospital records we recorded
hemoglobin (Hb), leucocytes with neutrophil count, pla-
telets, electrolytes, and C-reactive protein (CRP). Chest
radiographs were examined by two physicians blinded
for clinical data. Presence or absence of cephalisation,
pneumonic infiltrates and pleural effusion in addition to
the size of the heart and thoracic cavity in the frontal
plane were recorded. ECGs recorded on admission were
scored using CIIS. A score ≥20 has been shown to be a
good indicator of prior MI [17], and to be associated
with increased mortality in AECOPD patients [18]. Two
physicians independently scored each ECG. When they
disagreed on whether the CIIS was above or below 20,
the score of a third physician was used. All three investi-
gators were blinded to other data. ECGs were also ana-
lysed for the presence of arrhythmia, bundle branch
block, left ventricular hypertrophy (LVH, assessed by
Sokolow-Lyon criteria), signs of prior MI, or acute ische-
mia. We considered pathological Q-waves, loss of R-
waves, T-wave inversion, and left bundle branch block to
be signs of prior MI. ST-segment elevation or depression
were recorded as signs of acute ischemia unless it was
considered to be secondary to LVH.
Spirometry during stable phase was recorded when
available. When several measurements were done, post
bronchodilatation measurements prior to inclusion were
preferred. Body mass index (BMI) was calculated from
weight and height as recorded on the spirometry report
or from the hospital records when spirometry was miss-
ing. Medical history was obtained by patient interview
and hospital records. Patients were categorised as current,
former (>1 year abstinence) or never smokers. Further
details regarding patient inclusion and data gathering are
described in a previous paper [13].
T h es t u d yw a sa p p r o v e db yt h eD a t aI n s p e c t o r a t ea n d
reviewed by the Regional Committee for Research Ethics.
All included patients provided written informed consent to
the participation in the study.
Statistical analysis
Due to the skewed distribution of hs-cTnT, the natural
logarithm of hs-cTnT (lnTnT) was used as the
dependent variable in the analyses. Samples with hs-
cTnT below the limit of detection (i.e. 3.0 ng/L), were
assigned a value of 3.0. Outliers were identified by visual
inspection of the data points. Individual assessment of
outliers determined whether they were to be excluded
from further analyses. The analyses were performed in
four steps: First, we analysed cross-sectional associations
between lnTnT and variables recorded on the index ad-
mission using Student t-test. The continuous variables
were dichotomised at predifined cut-offs: Age at the
mean, FEV1/FVC at the lower quartile, BMI at the lower
limit of normal (i.e. 20 kg/m
2), HR at 100/min, MAP at
90 mmHg, creatinine and neutrophil count at the upper
quartile, pH at 7.30, PaCO2 at 6.3 kPa, PaO2 at 7.0 kPa,
Hb at 12 g/dL in women and 13 g/dL in men, CRP at
50 mg/L, and CIIS at 20 points. In addition, the associ-
ation between lnTnT and the following categorical vari-
ables were analysed: Gender, smoking status, history of
coronary artery disease, heart failure, arterial hyperten-
sion, atrial fibrillation or diabetes, use of beta blockers,
diuretics, ACE-inhibitors (ACEI) or angiotensin-II recep-
tor blockers (ARB), statins, acetylic salicylic acid, or
Warfarin, presence of atrial fibrillation, LVH, MI, or is-
chemia on ECG, peripheral edema, chest pain, and infil-
trate or cephalisation on chest radiograph. Associations
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were also analysed in a univariable linear regression
model.
Second, in patients with repeat admissions, we investi-
gated the level of lnTnT over time; first graphically and
then by using time and time squared as independent vari-
ables in a linear mixed model (LMM) [19].
In the third step, we investigated intra-individual uni-
variable associations between lnTnT and each of the con-
tinuous covariables. We identified the minimum and
maximum values of continuous time-dependent variables
along with the corresponding values of hs-cTnT. We then
analysed the univariable associations between lnTnT and
each of the continuous covariables using LMM with ran-
dom intercept. From these analyses, the antilogarithm exp
(β) of the coefficient (β) between lnTnTand each covariate
can be interpreted as the relative change in lnTnT for a
given change in the covariate.
Fourth, the variables that were associated with lnTnT
with a p-value <0.2 in the cross-sectional or longitudinal
analysis were included in the initial multivariable LMM. In
this model we investigated candidate covariance structures
and a model with random intercept. The models were
compared using the Akaike Information Criteria (AIC).
Using the model with the lowest AIC, we then manually
reduced the model by backward elimination of variables
with p-values <0.05 unless their removal increased the
AIC statistic. Finally, we investigated the changes made by
adding survival status and neutrophil count to the final
model. Gender was kept in the model by convention.
All analyses were performed in SAS 9.2 (SAS Institute
Inc., Cary, NC, USA), using PROC MIXED for the
LMM.
Results
Cross sectional analyses at baseline
Mean age at inclusion was 71.5 years (standard deviation
(SD) 9.0), mean FEV1/FVC was 45% (SD 0.14), and me-
dian hs-cTnT was 27.0 ng/L (interquartile range (IQR)
13.4–51.0). LnTnT was close to normally distributed
with mean 3.24 (SD 0.97), corresponding to a geometric
mean of hs-cTnT=25.6 ng/L. Of the 219 samples, two
(0.9%) had hs-cTnT below the detection limit. The distri-
bution of hs-cTnT and lnTnT are shown in Figures 1A
and 1B. An outlier (hs-cTnT=609 ng/L) was an 82 year
old male in GOLD stage II with a history of arterial
hypertension and heart failure who was admitted with
COPD symptoms and treated accordingly. He is
excluded from Figure 1A, but is included in Figure 1B
and the analyses.
Using the Cockcroft-Gault formula, mean GFR was
85 mL/min (SD 31). Using the MDRD formula, 15.5% of
the 219 samples had estimated GFR <60 mL/min/
1.73 m
2, and 2% were <30 mL/min/1.73 m
2.
Spirometry was available in 88 patients. 80 of these
(91%) were post bronchodilatation measurements. BMI
was unavailable in five patients, and arterial blood gas
was missing in eight. In total, complete datasets were
available for 202 admissions. The results of the cross sec-
tional univariable associations with hs-cTnT are shown
in Table 1 for those variables reaching a level of signifi-
cance of p <0.2. There were no significant associations
between neutrophil count or CIIS ≥20 (t-test p-values
0.692 and 0.367, respectively). Moreover, we did not find
any association between hs-cTnT and lung function. The
patients with FEV1/FVC in the lower quartile (<0.34%)
had a geometric mean of hs-cTnT=26.1 ng/L compared
Figure 1 Distribution of high-sensitivity cardiac troponin T. The distribution of high-sensitivity cardiac troponin T (hs-cTnT, left panel) and
their natural logarithms (lnTnT, right panel) in 219 admissions among 99 patients with acute exacerbation of COPD. In the left panel, an outlayer
(hs-cTnT=609 ng/L) has been removed.
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upper three quartiles (p=0.945). When restricting the
analysis to the 80 patients with post bronchodilatation
measurements, the p-value was 0.890. There was no sta-
tistically significant difference in hs-cTnT level among
patients who had spirometry recorded and those who
had not (geometric mean of 26.4 ng/L and 20.9 ng/L, re-
spectively, p=0.438).
Longitudinal analyses
41 patients had one or more (maximum 10) repeat admis-
sions, adding up to a total of 161 readmissions. Table 2
shows the intraindividual variation in continuous time-
dependent covariables and the corresponding hs-cTnT
values. It indicates a considerable intra-individual variation
of the covariables. However, as shown in Table 3 (two right
columns), univariable analyses revealed that only creatin-
ine, PaO2, and heart rate (borderline) were significantly
associated with lnTnT.
According to the criteria outlined above, the following
variables were included in the initial multivariable model:
age, gender, time since inclusion, history of coronary ar-
tery disease or arterial hypertension, smoking, BMI,
chest pain, Hb, creatinine, cephalisation, use of diuretics,
ACEI/ARBs or a statin, HR, PaCO2 and PaO2. In this
model BMI, Hb, HR, PaCO2, and PaO2 were dichoto-
mised as previously described. A model with fixed effects
only gave the lowest AIC statistic, and a spatial exponen-
tial covariance structure had the best fit. Reduction of
the full model gave the final model (model 1) shown in
Table 4. Even though both hypoxemia (15% increase in
hs-cTnT per kPa, p-value 0.086) and BMI <20 kg/m
2
(28% increase, p-value 0.144) failed to reach significance,
it is adjusted for in the final model as their removal
increased the AIC statistic.
When survival status was added to the final model, it
proved significantly associated with hs-cTnT, with a rela-
tive value of 1.58 (95% CI 1.11 – 2.23, p=0.011) among
Table 2 The median of the minimum and maximum values of selected continuous time-dependant covariables and the
corresponding values of high-sensitivity cardiac Troponin T in patients with repeat admissions for Acute Exacerbation
of COPD
Covariable (C) Corresponding hs-cTnT (ng/L)
Minimum, Maximum, At minimum C, At maximum C,
median (IQR) median (IQR) median (IQR) median (IQR)
MAP, mmHg 82.0 (71.7 – 93.7) 108.3 (92.0 – 126.7) 33.7 (18.8 – 60.8) 37.8 (18.3 – 72.4)
Creatinine, μmol/L 59 (47 – 67) 74 (60 – 91) 33.0 (19.6 – 60.3) 44.6 (21.2 – 77.4)
CRP, mg/L 10 (<5 – 20) 76 (26 – 141) 37.8 (19.2 – 72.4) 33.0 (22.0 – 60.3)
Neutrophil count, 10
9/mL 5.6 (4.2 – 7.7) 11.8 (9.0 – 16.7) 34.2 (18.8 – 66.7) 32.4 (21.9 – 60.3)
Hemoglobin, g/L 12.6 (11.5 – 13.9) 14.0 (13.0 – 15.3) 32.4 (19.6 – 53.1) 36.7 (19.2 – 64.4)
Heart rate, /min 88 (75 – 99) 117 (101 – 126) 33.9 (18.8 – 54.0) 37.8 (21.8 – 68.4)
PaCO2, kPa* 5.32 (5.0 – 6.4) 6.9 (5.9 – 8.4) 33.0 (18.3 – 60.3) 37.8 (25.6 – 63.0)
PaO2, kPa* 6.7 (6.0 – 8.1) 9.8 (8.7 – 10.9) 37.5 (22.4 – 77.4) 31.4 (18.1 – 61.0)
The table is based on 161 admissions in 41 patients.
* Missing in eight admissions. Hs-cTnT, high-sensitivity cardiac troponin T; IQR, interquartile range; MAP, Mean arterial pressure; CRP, C-reactive protein.
Table 1 Geometric mean of high-sensitivity cardiac
Troponin T (hs-cTnT) by covariables associated with
lnTnT (Student t-test p<0.20)
Geometric mean of
hs-cTnT, ng/L
(number of patients)
Covariable No Yes p-value
Demographics and medical history
Age >71.5 years * 16.9 (50) 38.9 (49) <0.0001
Female 29.1 (52) 22.2 (47) 0.153
Coronary artery disease 28.8 (72) 18.9 (27) 0.058
Arterial hypertension 21.8 (68) 37.0 (31) 0.011
Current or recent smoker 37.4 (48) 22.2 (51) 0.166
BMI <20 kg/m
2 22.9 (62) 33.1 (32) 0.083
Clinical findings
Chest pain 26.8 (89) 16.4 (10) 0.130
Heart rate ≥100/minute 28.2 (49) 23.3 (50) 0.052
Laboratory tests
Low hemoglobin
† 23.1 (76) 36.6 (23) 0.045
Creatinine >86 μg/L
{ 22.4 (69) 34.8 (30) 0.038
Chest radiograph
Cephalisation 23.8 (83) 37.0 (16) 0.096
Medication on admission
Diuretic (loop or thiazid) 22.6 (73) 36.2 (26) 0.033
ACEI or ARB 23.6 (76) 33.8 (23) 0.124
Statin 27.9 (79) 18.0 (20) 0.070
The table is based on each patient’s index admission only.
*Corresponds to the mean age;
†Defined as Hb <12 g/L in women and
<13 g/L in men;
{Corresponds to the upper quartile; ACEI, angiotensin
converting enzyme-inhibitor; ARB, angiotensin receptor blocker.
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2 in Table 4. The interaction term time*survival status
was not statistically significant (p-value 0.095). When
added to the final model, neutrophil count failed to
reach significance both as a continuous variable (7% in-
crease in hs-cTnT per 5 cells, p=0.160) and dichoto-
mised at the upper quartile (relative change of 15%,
p=0.085).
Removing the outlier from the analyses made no sig-
nificant changes in any of the results above.
Discussion
In this study hs-cTnT was positively associated with age,
history of arterial hypertension, tachycardia, creatinine,
and follow-up time among patients hospitalised for
AECOPD. The strength of this study is that the patients
were followed prospectively, and that as many as 41% of
the patients were investigated at two or more admis-
sions. Consequently, the associations could be investi-
gated longitudinally as well as cross-sectionally. We have
also used the novel highly sensitive cardiac troponin T
assay, allowing us to measure concentrations down to
about 1/10 of what was previously possible, finding de-
tectable cTnT in almost all samples.
Regarding the association between hs-cTnT and arter-
ial hypertension, one might speculate that this was due
to the development of LVH, as LVH have been found to
be associated with troponin in other studies [20,21].
However, there was no significant association between
troponin and electrocardiographic signs of LVH in the
present study. An alternative explanation may be the
established role of arterial hypertension as a risk factor
for the development of CVD.
The association between hs-cTnT level and creatinine
deserves some comment. In clinical practice, we often ex-
perience elevated levels of troponin in patients with renal
failure, but without overt cardiac disease. It has been previ-
ously debated whether this is due to reduced renal elimin-
ation of troponin, but it may rather be a result of subclinical
release of cTnT in these patients, as renal and cardiac
Table 3 Univariable associations, expressed as the antilogarithm (exp(β)) of the coefficient β, between continuous time
dependent covariables and the natural logarithm of hs-cTnT (lnTnT) assessed using an ordinary least square linear
regression model (OLS, index admission) and a linear mixed model (LMM, repeat admissions)
Interindividual associations between
covariables and lnTnT (OLS)
Intraindividual associations between
covariables and lnTnT (LMM)
Index admission in 99 patients 161 repeat admissions in 41 patients
Covariable Change in covariable exp(β) (95% CI) p-value exp(β) (95% CI) p-value
MAP +5 mmHg 1.002 (0.951 – 1.06) 0.944 1.003 (0.98 – 1.03) 0.792
Creatinine +10 μmol/L 1.08 (1.03 – 1.14) 0.004 1.10 (1.04 – 1.16) 0.0004
CRP +10 mg/L 1.01 (0.97 – 1.05) 0.680 1.005 (0.99 – 1.02) 0.478
Neutrophil count +5x10
9/mL 0.93 (0.75 – 1.17) 0.555 1.005 (0.99 – 1.02) 0.468
Hemoglobin +1 g/L 0.96 (0.85 – 1.08) 0.477 1.03 (0.68 – 1.6) 0.902
Heart rate +5 bpm 0.98 (0.94 – 1.02) 0.392 1.02 (0.998 – 1.04) 0.078
PaCO2* +1 kPa 1.09 (0.96 – 1.24) 0.195 1.05 (0.98 – 1.12) 0.144
PaO2* +1 kPa 0.97 (0.87 – 1.08) 0.573 0.96 (0.94 – 0.99) 0.008
*Missing in eight admissions. OLS, ordinary least square linear regression model; LMM, linear mixed model; MAP, Mean arterial pressure; bpm, beats per minute.
Table 4 Relative change in hs-cTnT (95% confidence interval) by changing covariables on admission for Acute
Exacerbation of COPD
Model 1 Model 2
Covariable Change in covariable Relative change in hs-cTnT p-value Relative change in hs-cTnT p-value
Time independent
Age at inclusion +5 years 1.24 (1.13 – 1.37) <0.0001 1.19 (1.08 – 1.31) 0.0005
History of HT Yes vs. no 1.44 (1.03 – 2.01) 0.034 1.29 (0.92 – 1.80) 0.138
Time dependent
Heart rate ≥100/min Yes vs. no 1.25 (1.01 – 1.54) 0.042 1.24 (1.02 – 1.52) 0.036
Creatinine +10 μmol/L 1.05 (1.003 – 1.09) 0.037 1.04 (1.002 – 1.09) 0.037
Time since inclusion +1 month 1.02 (1.0004 – 1.05) 0.046 1.02 (0.99 – 1.05) 0.051
Obtained from a linear mixed model using 202 admissions among 94 patients.
Model 1 is adjusted for gender, hypoxemia, and BMI <20 kg/m
2. Model 2 is additionally adjusted for survival status. hs-cTnT, high-sensitivity cardiac troponin T; HT,
arterial hypertension.
Høiseth et al. BMC Pulmonary Medicine 2012, 12:22 Page 5 of 7
http://www.biomedcentral.com/1471-2466/12/22atherosclerotic disease are pathophysiologically similar and
partly overlapping. It may be worth noting that the majority
of our patients had normal creatinine, an observation that
favors the latter of the two theories. It may be argued that
due to reduced muscle mass, patients with advanced COPD
may have decreased renal function in spite of creatinine
within the reference range. The finding that the addition of
low BMI improves the fit of the final model, adds to this ar-
gument. We therefore estimated GFR, but still found that
renal function was preserved in the vast majority of
patients.
Although the cross-sectional analyses of the baseline
data indicated an inverse association between tachycardia
and hs-cTnT, longitudinal multivariable analysis showed
a significant positive association between elevated hs-
cTnT and tachycardia. This may be due to an effect of
heart rate per se, but it may also reflect worsening of
pulmonary hypertension and increased myocardial strain,
undiagnosed pulmonary embolism, or a type 2 MI
caused by insufficient oxygen delivery relative to the
increased demand during tachycardia. Along this line of
thinking, we would also expect an association between
reduced PaO2 and hs-cTnT. Although we found such an
association in the univariable longitudinal analysis, it was
not significant in the cross sectional or multivariable
analyses. Hence, our data do not support that elevated
hs-cTnT in these patients can be explained as a type 2
MI mediated hypoxemia. However, patients with normal
arterial oxygen tension in the emergency room may have
received oxygen therapy in the ambulance, yet have had
severe arterial hypoxemia before admission to the hos-
pital causing cTnT leakage from the cardiomyocytes.
Thus, the lack of association between hypoxemia and
elevated hs-cTnT should be interpreted with caution.
Our analyses are based on data from repeat admissions
by applying the linear mixed model [19]. Among the
strengths of the model is that it does not require the out-
come variable to be independent between observations,
so one can use repeat observations from the same indi-
vidual. Moreover, by using an appropriate covariance
structure, the model allows us to have unbalanced data
with different number of observations per patient and
different timing of these. Thus, the analyses are based
not only on inter-individual differences, but also on
intra-individual changes in covariables over time, effect-
ively allowing patients with repeat admissions to serve as
their own controls. Hence, the association between hs-
cTnT and covariables (such as oxygen tension and cre-
atinine changes) can be investigated intra-individually.
Comparison of the results of these univariable analyses
show that the associations with creatinine were highly
significant in the cross-sectional as well as in the longitu-
dinal models with the estimates being nearly identical.
There is discrepancy regarding heart rate, with p-value
<0.10 in the LMM only. Although the design of the
study does not permit any conclusions to be drawn
regarding cause and effect, this discrepancy may suggest
that there is an association between tachycardia and
cTnT release in susceptible individuals.
Our group has previously published results from a
retrospective cohort study of 441 patients with AECOPD,
identifying creatinine, hemoglobin, neutrophil count, heart
rate and CIIS as independent predictors of elevated cTnT
(≥0.04 μg/L) [14]. In the present prospective study, we
confirm that age, creatinine, and heart rate are independ-
ently associated with hs-cTnT level. In addition, we
observed an association between hs-cTnT and history of
arterial hypertension. CIIS and neutrophil count were not
significantly associated in the present analyses, perhaps
due to the relatively modest sample size. On the other
hand, considerable intra-individual variation of neutrophil
count was observed, thereby weakening the hypothesis of a
relationship between neutrophils and cTnT. Other markers
of inflammation than leucocytes, fibrinogen in particular,
have been shown to be associated with COPD, its severity
and exacerbation frequency [22-27]. Fibrinogen was not
measured in this study, but one might speculate
whether this inflammatory marker might be more
closely associated with cTnT, as it may be a risk fac-
tor for the development of CVD.
Other limitations of this study include the modest size
of the cohort, which may explain the inconsistency regard-
ing tachycardia, and the nonsignificant association with
hypoxemia. Nevertheless, we identify associations that are
both statistically significant and physiologically plausible.
The strengths of the associations may be unimpressive,
with an estimated 44% increase in hs-cTnT in patients
with hypertension as the strongest association. The range
of hs-cTnT concentrations is small, however, so strong
associations can not be expected. Moreover, in spite of this
narrow range, relatively small changes in hs-cTnT are
associated with markedly adverse prognosis in this group
[13]. Thus, it is important to identify determinants of
cTnT elevation in AECOPD.
Although patients with confirmed PE were excluded
from the study, the diagnosis was not systematically
investigated, and unrecognised PE may have influenced
the results.
Conclusion
Age, arterial hypertension, tachycardia, and serum cre-
atinine are independently associated with the level of hs-
cTnT at admission for AECOPD.
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